BridgeMD
New treatment option for Intravascular Imaging and Microvascular Obstruction
Official title Study on the Improvement of Myocardial Microcirculation After Acute Anterior Myocardial Infarction
ClinicalTrials.gov ID: NCT06154395
What this study is testing
- What it's testing
- This study is a prospective, single-center, randomized controlled clinical trial. Ninety patients with anterior wall ST-segment elevation myocardial infarction (STEMI) who are planned for primary percutaneous coronary intervention (PCI) within 6 hours of symptom onset will be screened.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Clinical
- people aged ≥18 years;
- Initial diagnosis of anterior wall ST-segment elevation myocardial infarction, with symptoms occurring within 6 hours, and undergoing...
- people (or legal representatives) who understand the study requirements and treatment procedures and provide signed informed consent. Imaging (Visual...
- Target lesion is the culprit lesion, located in the native coronary artery, with a visually estimated reference vessel diameter (RVD) between 2.25 mm...
You likely can't join if
- Clinical Exclusion Criteria:
- History of coronary artery bypass grafting (CABG);
- Known history of myocardial infarction or PCI;
- Previous thrombolytic therapy before PCI;
- Severe liver or kidney dysfunction, severe valvular heart disease, chronic obstructive pulmonary disease, etc.;
- Contraindications to magnetic resonance imaging;
See the full eligibility criteria
- Clinical
- people aged ≥18 years;
- Initial diagnosis of anterior wall ST-segment elevation myocardial infarction, with symptoms occurring within 6 hours, and undergoing primarypercutaneous coronary intervention (PCI);
- people (or legal representatives) who understand the study requirements and treatment procedures and provide signed informed consent. Imaging (Visual Estimation):
- Target lesion is the culprit lesion, located in the native coronary artery, with a visually estimated reference vessel diameter (RVD) between 2.25 mm and 4.0 mm;
- Culprit segment of the infarct-related artery (IRA) is located between the origin of the left anterior descending (LAD) artery and the emergence of the second diagonal branch (D2);
- After pre-treatment , the degree of stenosis in the LAD is ≤90%, and TIMI flow is grade 3.
- Clinical Exclusion Criteria:
- History of coronary artery bypass grafting (CABG);
- Known history of myocardial infarction or PCI;
- Previous thrombolytic therapy before PCI;
- Severe liver or kidney dysfunction, severe valvular heart disease, chronic obstructive pulmonary disease, etc.;
- Contraindications to magnetic resonance imaging;
- Allergy to gadolinium contrast agents and/or accompanying medications for devices or procedures (e.g., any component of drug-eluting stents, all P2Y12 inhibitors, or aspirin);
- Expected lifespan of the subject less than 12 months;
- Pregnant or lactating females;
- Other people deemed unsuitable for participation in the study by the investigator. Imaging Exclusion Criteria (Visual Estimation):
- Presence of lesions requiring intervention other than the target lesion at baseline surgery;
- No protected left main coronary artery disease (visual estimate of stenosis \>50%);
- Diffuse severe calcification (\>20 mm) or chronic total occlusion in the major coronary vessels (LCX, RCA);
- Severe coronary artery tortuosity (\>45°) or calcification (\>270°), or other conditions that may interfere with the use of intravascular imaging.
The study team makes the final eligibility decision.
Where it's taking place
- Harbin, Heilongjiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Harbin, Heilongjiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.